Your browser doesn't support javascript.
loading
Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.
Swamy, Manjunath N; Wu, Haoquan; Shankar, Premlata.
Afiliação
  • Swamy MN; Center of Emphasis in Infectious Disease, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA. Electronic address: Manjunath.swamy@ttuhsc.edu.
  • Wu H; Center of Emphasis in Infectious Disease, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.
  • Shankar P; Center of Emphasis in Infectious Disease, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA. Electronic address: Premlata.shankar@ttuhsc.edu.
Adv Drug Deliv Rev ; 103: 174-186, 2016 08 01.
Article em En | MEDLINE | ID: mdl-27013255
ABSTRACT
RNA interference (RNAi) provides a powerful tool to silence specific gene expression and has been widely used to suppress host factors such as CCR5 and/or viral genes involved in HIV-1 replication. Newer nuclease-based gene-editing technologies, such as zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN) and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, also provide powerful tools to ablate specific genes. Because of differences in co-receptor usage and the high mutability of the HIV-1 genome, a combination of host factors and viral genes needs to be suppressed for effective prevention and treatment of HIV-1 infection. Whereas the continued presence of small interfering/short hairpin RNA (si/shRNA) mediators is needed for RNAi to be effective, the continued expression of nucleases in the gene-editing systems is undesirable. Thus, RNAi provides the only practical way for expression of multiple silencers in infected and uninfected cells, which is needed for effective prevention/treatment of infection. There have been several advances in the RNAi field in terms of si/shRNA design, targeted delivery to HIV-1 susceptible cells, and testing for efficacy in preclinical humanized mouse models. Here, we comprehensively review the latest advances in RNAi technology towards prevention and treatment of HIV-1.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome da Imunodeficiência Adquirida / HIV-1 / Interferência de RNA / Terapêutica com RNAi Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Adv Drug Deliv Rev Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome da Imunodeficiência Adquirida / HIV-1 / Interferência de RNA / Terapêutica com RNAi Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Adv Drug Deliv Rev Ano de publicação: 2016 Tipo de documento: Article